CA-FOCAL-SYSTEMS
16.3.2022 18:58:07 CET | Business Wire | Press release
On their mission to automate and optimize brick and mortar retail with state-of-the-art AI and deep learning, Focal Systems is proud to announce the launch of the world’s first “Self-Driving Store”-Operating System powered by computer vision and AI, called FocalOS. After 7 years hardening the platform with the largest retailers in the world, Focal's “Self-Driving Store”-Operating System is now Generally Available.
Enabled by AI-powered Shelf Cameras, FocalOS leverages computer vision and deep learning technology to provide real-time shelf digitization. This digitization feeds FocalOS, which automates order writing and ordering, directs stockers to double their productivity, optimizes category management on a per store basis, manages e-comm platforms to eliminate substitutions, tracks productivity per associate to drive further efficiencies, and much more. With FocalOS, corporate leaders can "teleport" into any store from anywhere in the world in seconds to see exactly what their shelves look like and how their stores are performing.
Major retailers have proven >50x ROI with FocalOS, making this the most profitable investment in all of retail technology.
Francois Chaubard, Founder and CEO, will unveil this solution in depth at the FMI Midwinter Conference in Orlando, Fla. on March 29.
Retailers have incredibly challenging jobs. Managing thousands of SKUs, employees, stores and ecommerce, while facing rising labor and supply chain costs and the evergreen battle for market share. Since 2015 our team has worked with leading global retailers to invent and implement AI solutions that drive true innovation, transformative financial returns and happy customers.
-Francois Chaubard - Founder/CEO Focal Systems
Focal has worked with leading retailers across North America, Europe and Australia and deployed more than 50,000 cameras worldwide. This launch enables retailers the ability to run fully automated “Self-Driving Stores" that achieve unprecedented labor efficiencies and sales growth just by setting the store on "Cruise Control" and letting the AI take it from there.
We’re always striving for more ways to improve the shopping experience for our customers. Focal is helping us use technology to improve our on-shelf customer availability, so our customers can find what they are looking for each time they choose to shop in-store with us.”
-Sam Wankowski - Chief Operations Officer, Walmart Canada
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state of the art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”-Operating System that revolutionizes how stores are run. Focal has raised more than $40m to date, and scaled their solutions to three continents and hundreds of stores, with thousands of cameras deployed. The Focal team is a carefully selected group of retail operations and AI experts who together have designed the next generation of operating systems for brick and mortar retail that leverages state-of-the-art AI and retail best practices to automate and optimize brick and mortar and on-line stores today.
Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom